Novo Nordisk (20 August 2007) announced clinical results from the second and third of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The two 26-week studies are part of the LEAD® (Liraglutide Effect and Action in Diabetes)... -> click here to read the Novo Nordisk's Press Release. (PDF Version)Blog Archive
-
▼
2007
(88)
-
▼
August
(15)
- Needle-Free Drug Delivery Technology for Diabetes ...
- BodyTel Scientific to Exhibit the GlucoTel System ...
- Pfizer and Bristol-Myers Squibb Worldwide Collabor...
- Teijin and Chugai, agreement to co-develop Ipsen's...
- Cannasat Therapeutics, Commence Phase 1 Study of C...
- AtheroGenics , Phase III clinical trial of AGI-106...
- Blood Glucose Meter, Medtronic and LifeScan Annou...
- Sirtris Pharmaceuticals, SRT501 product candidate ...
- Blood Glucose Meter, Medtronic and Bayer Diabetes ...
- Novo Nordisk, Liraglutide improves glucose control
- Diabetic Neuropathic Pain, UCB's subsidiary SCHWAR...
- Oramed oral insulin gel capsule
- CombinatoRx CRx-401 for Type 2 Diabetes
- Avigen, Neuropathic Pain : Clinical Development fo...
- a news diabetes blog
-
▼
August
(15)
Tuesday, August 21, 2007
Novo Nordisk, Liraglutide improves glucose control
Novo Nordisk (20 August 2007) announced clinical results from the second and third of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The two 26-week studies are part of the LEAD® (Liraglutide Effect and Action in Diabetes)... -> click here to read the Novo Nordisk's Press Release. (PDF Version)
